deltatrials
Completed PHASE3 NCT00964028

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) in Infants

Sponsor: GlaxoSmithKline

Conditions Acellular Pertussis Diphtheria Haemophilus Influenzae Type b Poliomyelitis Tetanus
Interventions Infanrix™-IPV/Hib
Updated 8 times since 2017 Last updated: Apr 27, 2018 Started: Dec 1, 2009 Primary completion: Apr 12, 2010 Completion: Apr 12, 2010

Listed as NCT00964028, this PHASE3 trial focuses on Acellular Pertussis and Diphtheria and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jul 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. May 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Feb 2017 — May 2017 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Wuzhou, China